Core Viewpoint - Phio Pharmaceuticals has received a positive recommendation from the Safety Monitoring Committee to escalate the dose in its Phase 1b clinical trial for PH-762, indicating a promising safety profile and potential efficacy in treating certain skin cancers [2][3][5]. Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company focused on developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology, aimed at enhancing the immune system's ability to target and kill cancer cells [3][5]. Clinical Trial Details - The Phase 1b clinical trial for PH-762 involves patients with cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The second cohort included 4 patients, with the first two showing a complete response (100% tumor clearance) and a partial response (90% clearance) at Day 36 [4][6]. - The intratumoral injections of PH-762 have been well tolerated, with no dose-limiting toxicities or serious adverse events reported [5][6]. Product Information - PH-762 is designed to silence PD-1 and represents a potential non-surgical treatment option for skin cancers. The trial received FDA clearance for an Investigational New Drug Application in the second quarter of 2023 [6].
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762